[{"orgOrder":0,"company":"Kaerus Bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"KER-0193","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Kaerus Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kaerus Bioscience \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Kaerus Bioscience \/ Undisclosed"},{"orgOrder":0,"company":"Kaerus Bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"KER-0193","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Kaerus Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kaerus Bioscience \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Kaerus Bioscience \/ Undisclosed"},{"orgOrder":0,"company":"Kaerus Bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"KER-0193","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Kaerus Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kaerus Bioscience \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Kaerus Bioscience \/ Undisclosed"},{"orgOrder":0,"company":"Kaerus Bioscience","sponsor":"Servier","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Miscellaneous","year":"2025","type":"Acquisition","leadProduct":"KER-0193","moa":"BK channel","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Kaerus Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kaerus Bioscience \/ Kaerus Bioscience","highestDevelopmentStatusID":"8","companyTruncated":"Kaerus Bioscience \/ Kaerus Bioscience"}]